Related Experiment Video
Updated: Jun 14, 2025
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Dose, Kidney Function, and a Drug-Excipient Interaction Impair Mycophenolate Mofetil Prodrug Activation in Kidney
Fleur B Nijdam1, Marieke A J Hof2, Daan Kremer3
1Unit of PharmacoTherapy, -Epidemiology, and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
Background And Objective:
Current immunosuppressive treatment to prevent graft rejection in organ transplant recipients commonly includes mycophenolate mofetil (MMF) and a calcineurin inhibitor. After absorption, MMF is activated to mycophenolate (MPA) by the carboxylesterase (CES) enzymes, which is considered to occur rapidly and completely. Recent research utilizing pharmacometabolomics (PMx), however, identified an unknown/unreported MMF glucuronide metabolite in several kidney transplant recipients (KTR). This finding indicates incomplete MMF prodrug activation by CES, thereby suggesting enzyme saturation and/or inhibition, which warrants further study. In this work, we aimed to identify clinical factors that could (partially) explain incomplete MMF activation as observed in KTR.
Methods:
We analyzed untargeted urinary PMx data to determine MMF prodrug activation in 321 KTR from the TransplantLines Biobank and Cohort Study (NCT03272841) and 403 KTR from the TransplantLines Food and Nutrition Biobank and Cohort Study (NCT02811835). Beta regression was used to associate incomplete MMF activation with clinical parameters. Subsequently, in vitro experiments using human S9 liver extracts were performed to compare the influence of potential CES inhibitors on MMF activation.
Results:
Beta regression linked an impaired MMF activation with increasing MMF dose and kidney function as well as with cyclosporine (CsA) use. Regarding the latter, in vitro experiments revealed a decreased MMF activation caused by the pharmaceutical excipient Kolliphor® EL, which is present in CsA capsules, rather than by CsA itself.
Conclusion:
Substantially reduced MMF prodrug activation was observed in large numbers of KTR, indicating relevant attenuation of the MMF-converting CES enzymes, which may be due to enzyme saturation and inhibition. However, there may be other factors affecting MMF activation, which require elucidation to improve immunosuppression therapy.
Insights
Incomplete activation of mycophenolate mofetil (MMF) was observed in kidney transplant recipients (KTR). This reduced MMF activation is linked to MMF dose, kidney function, and cyclosporine excipients, impacting immunosuppression therapy.
Area of Science:
- Pharmacology
- Transplantation Medicine
- Metabolomics
Background:
- Mycophenolate mofetil (MMF) is a key immunosuppressant for organ transplant recipients.
- MMF is activated to mycophenolic acid (MPA) by carboxylesterase (CES) enzymes.
- Recent pharmacometabolomics (PMx) studies suggest incomplete MMF activation in kidney transplant recipients (KTR).
Purpose of the Study:
- To identify clinical factors contributing to incomplete MMF prodrug activation in KTR.
- To investigate potential mechanisms behind reduced MMF activation.
Main Methods:
- Analysis of untargeted urinary PMx data from 724 KTR.
- Beta regression to correlate incomplete MMF activation with clinical parameters.
- In vitro experiments using human liver extracts to assess potential CES inhibitors.
Main Results:
- Impaired MMF activation was associated with higher MMF dose, poorer kidney function, and cyclosporine (CsA) use.
- In vitro studies identified Kolliphor® EL, an excipient in CsA capsules, as a cause of reduced MMF activation, not CsA itself.
Conclusions:
- Significant MMF prodrug activation impairment occurs in KTR, suggesting CES enzyme saturation or inhibition.
- Excipients in co-administered medications may significantly affect MMF activation.
- Further research is needed to fully understand and optimize MMF activation for improved immunosuppression outcomes.
Related Concept Videos
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:09Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
01:31Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:19Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:15Drug Elimination by Renal Route: Tubular Secretion